SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Ernest Hemingway

PatientErnest Hemingway
Date of birth1970-07-21
IdentifiersMRN HR-ET003-SYN; SSN (made up) 000-03-7419
Document date2026-03-16
AuthorWalter Brandt-Ochoa, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review, seen the same day by hepatology. [S]

History of Present Illness

Mr. Hemingway returns two weeks after intake and is seen by Dr. Solheim of hepatology on the same day. The HFE test drawn at intake shows that he is homozygous for C282Y. He has taken naltrexone 50 mg daily; he had mild nausea for three days, which passed. By his diary he has cut down from about ten drinks a day to five or six, with none before evening on most days. He has had no tremor, sweats or trouble sleeping beyond his usual. He has taken sertraline 50 mg daily with loose stools for a few days and no other side effects. His home blood pressure average is 146/90 on amlodipine 5 mg. His guns were taken to the locked storage at his shooting club the week after intake, and he keeps no ammunition at home. He has started weekly psychotherapy. His headaches are unchanged, two or three a week. [S]

ElementDetail
HFE genotypeC282Y homozygous
AlcoholFive or six drinks a day, down from about ten; none before evening
Naltrexone50 mg daily; nausea for three days, now gone
Sertraline50 mg daily for two weeks; loose stools for a few days
Home blood pressureAverage 146/90
FirearmsStored at his shooting club since last week; no ammunition at home

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; tiredness unchanged
GastrointestinalPositiveNausea for three days on starting naltrexone, now gone; no abdominal pain or jaundice
NeurologicalPositiveHeadaches two or three times a week; no tremor
PsychiatricPositiveMood still low; no thoughts of suicide or wishes to be dead since the last visit

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naltrexone 50 mg oral tablet, one tablet daily, to reduce heavy drinkingOne tablet dailyOral route2026-03-02activeS
Thiamine 100 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-02 to 2026-08-31completedS
Sertraline 50 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-02 to 2026-04-13completedS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-02 to 2026-06-08completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-16Body height183cmS
2026-03-16Body weight97.4kgS
2026-03-16Body mass index (BMI) [Ratio]29.1kg/m2S
2026-03-16Systolic blood pressure144mm[Hg]S
2026-03-16Diastolic blood pressure90mm[Hg]S
2026-03-16Heart rate84/minS
2026-03-16Respiratory rate16/minS
2026-03-16Body temperature36.7CelS
2026-03-16Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-16Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma58U/L10-40 U/LHighS
2026-03-16Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma66U/L7-55 U/LHighS
2026-03-16Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma160U/L8-61 U/LHighS
2026-03-16Ferritin [Mass/volume] in Serum or Plasma1395ng/mL24-336 ng/mLHighS
2026-03-16Liver stiffness by US.transient elastography9.4kPaBelow 7.0 kPa makes significant fibrosis unlikely; 12.5 kPa or more suggests cirrhosisHighS

Physical Exam

Vital signs recorded on 2026-03-16; see the Vital Signs section. [S]

SystemFinding
GeneralAlert; no smell of alcohol; blood pressure 144/90, pulse 84; weight 97.4 kg
AbdomenLiver edge palpable 1 cm below the costal margin, smooth and non-tender; no spleen felt; no ascites
SkinNo jaundice, spider naevi or palmar erythema; no bronze pigmentation
NeurologicalNo tremor; gait steady
PsychiatricEngaged and direct; mood low

Problems

ProblemClinical statusVerificationCodeProvenance
Alcohol use disorder, severe; heavy daily drinking for most of his adult life; synthetic modern episode linked to his documented heavy drinkingactiveconfirmed F10.20S — Synthetic modern coding of DSM-5-TR severe alcohol use disorder (seven criteria); person-first language; not a claim about his real diagnosis.
Raised transferrin saturation and ferritin found on routine intake tests, cause not yet known (heavy drinking, liver disease or iron overload)resolvedconfirmed R79.0S — Synthetic presenting finding; superseded when HFE testing gave the diagnosis.
Hereditary hemochromatosis, HFE C282Y homozygous, with iron overload (ferritin over 1,000 ng/mL) and no advanced liver fibrosis on imagingactiveconfirmed E83.110S — Synthetic modern diagnosis. Whether he had hemochromatosis is disputed (CLM-0013); the modern diagnosis is not offered as proof of it.
Major depressive disorder, single episode, moderate; Mood Disorder Questionnaire negative and no history of mania or hypomaniaactiveconfirmed F32.1S — Synthetic modern diagnosis; not a claim about his real mood. The roster's bipolar disorder lead is disputed (CLM-0014) and is not used.
Essential hypertension, stage 2, with heavy drinking contributingactiveconfirmed I10S — Synthetic modern diagnosis confirmed by home readings.
Post-concussion symptoms (headaches, slowed thinking and forgetfulness) after repeated head injuries, most recently a concussion with a skull fracture a year ago; chronic traumatic encephalopathy is not diagnosedactiveconfirmed F07.81S — Synthetic modern diagnosis anchored to his documented head injuries; alcohol and depression also affect the symptoms.
Prediabetes (HbA1c 6.1%)activeconfirmed R73.03S — Synthetic finding on diabetes screening; iron overload and alcohol both raise the risk of diabetes.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHFE genotypingOnce, when transferrin saturation is 45% or more with a raised ferritinCompleted todayC282Y homozygous (result of the intake sample, reported as narrative)
LaboratorySerum ferritin during induction phlebotomyAt diagnosis, then about every 10 to 12 phlebotomies; target 50 to 100 ng/mLCompleted todayFerritin 1,395 ng/mL before the first phlebotomy
LaboratoryTransferrin saturationAt diagnosis and as ferritin nears targetUp to date76% at intake
ImagingLiver fibrosis staging (ferritin over 1,000 ng/mL and raised ALT)Once at diagnosis: elastography, MRI or biopsyCompleted todayTransient elastography 9.4 kPa (indeterminate); controlled attenuation parameter 288 dB/m; MRI with iron quantification and elastography ordered instead of a biopsy
Medication safetyWeekly phlebotomy of 500 mLWeekly during inductionOrderedFirst session next week
Self-managementDiet: no iron or vitamin C supplements, no raw shellfishEvery visitCompleted todayExplained with a written sheet; he takes no supplements
ReferralTesting offered to first-degree relativesAt diagnosisCompleted todayLetter for first-degree relatives given to him; whether to share it is his choice; no relative's result is recorded
LaboratoryLiver tests on naltrexoneBaseline, about one month, then every three to six monthsCompleted todayAST 58, ALT 66 and GGT 160 U/L, falling from 70, 78 and 196
SurveyDrinking quantity and goal (AUDIT-C, drinking diary)Every visitCompleted todayDiary: five or six drinks a day; AUDIT-C next at the six-week visit
Medication safetyOpioid use and pain plan on naltrexoneEvery visitCompleted todayNo opioids; wallet card explaining naltrexone
ExaminationAlcohol withdrawal risk and symptoms when cutting down or stoppingEach visit while cutting downCompleted todayNo tremor, sweating or tachycardia; reducing gradually
Medication safetyThiamineDaily while drinking heavilyCompleted todayTaking thiamine 100 mg daily
SurveyDepression (PHQ-9)At least monthly during acute treatmentUp to datePHQ-9 16 two weeks ago; next at the six-week visit
Medication safetySertraline adherence and side effectsTwo weeks after starting or changing the dose, then each visitCompleted todayTwo-week review: loose stools for a few days; continue 50 mg
SurveySuicide-risk review (C-SSRS screen since the last visit), safety plan, firearm storage and the 988 Suicide & Crisis LifelineEvery visitCompleted todayC-SSRS screen negative since the last visit; firearms stored off-site; safety plan reviewed
Self-managementPsychotherapy (CBT)WeeklyCompleted todayFirst session last week
ExaminationBlood pressure, home readings, weight and cardiac auscultationEvery visitCompleted today144/90 in clinic; home average 146/90; weight 97.4 kg; no murmur
ImagingEchocardiogramAt diagnosis of stage 2 hypertensionOrderedOrdered at intake; not yet scheduled
ExaminationPost-concussion symptoms (headache frequency, sleep, concentration)Every visitCompleted todayHeadaches two or three times a week; sleeping six hours
ReferralHepatology consultationAt diagnosis of iron overload with raised liver testsCompleted todaySeen by Dr. Solheim today

Goal progress:

Guideline basis: Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011); ACG Clinical Guideline: Hereditary Hemochromatosis (2019); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026)

Follow-up: Weekly phlebotomy from next week. MRI of the liver within four weeks. Six-week review in four weeks with blood count, ferritin, liver tests, PHQ-9 and AUDIT-C. Weekly psychotherapy. Next scheduled visit 2026-04-13: six-week review: phlebotomy, drinking, mood, blood pressure and liver imaging. [S]